10P - Influence of tumor necrosis factor-alpha-thymosin-alpha1 on the humoral and cellular immunity of patients with locally advanced breast cancer

Date 21 November 2014
Event ESMO Symposium on Immuno-Oncology 2014
Session Welcome reception and Poster viewing
Topics Breast Cancer, Locally Advanced
Cancer Immunology and Immunotherapy
Translational Research
Presenter Liubov Vladimirova
Authors L.Y. Vladimirova1, N. Podzorova1, E. Zlatnik2, G. Zakora2, A. Bakhtin3, V. Myagkova1
  • 1Chemotherapy, Rostov Scientific Research Institute of Oncology, 344037 - Rostov-on-Don/RU
  • 2Laboratory Of Immunophenotyping Of Tumors, Rostov Research Oncological Institute, 344037 - Rostov on Don/RU
  • 3Laboratory Of Immunophenotyping Of Tumors, Rostov Research Oncological Institute, 344037 - Rostov-on-Don/RU

Abstract

Body

Background: The purpose of the study was to assess the effect of recombinant hybrid protein of tumor necrosis factor-alpha-thymosin-alpha1 (TNF-T) on B-cell component of the immune system of patients with locally advanced breast cancer (LABC).

Methods: Eligibility criteria included LABC of IIB-IIIB stages, ECOG = 1, adequate liver, kidney and bone marrow function, no brain metastases. TNF-T 200000 IU was injected locally around the tumor on D1-5 (30 min before cytostatics injection), combined with standard FAC or PA regimens.

Results: 56 women were recruited between April 2012 and October 2013 (mean age 53.3 ± 1.1 years). Group A (25 pts) received TNF-T combined with PA (17) and FAC (8) up to 4 courses. Group B (31pts) received standard PA (21) and FAC (10) up to 6 courses. Immune status in both groups of patients was assessed before the treatment and after neoadjuvant chemotherapy (CT). The study showed that levels of T-lymphocytes and CD3 + CD4+ cells did not differ significantly neither in comparison of groups A and B nor in the course of treatment. Quantity of CD3 + CD8+ cells in group A (PA) was significantly higher than in group B (PA) (31.5 ± 2.8% and 21.7 ± 2.25%, respectively, p < 0.05). Content of B-lymphocytes (CD20) decreased during the treatment in group B (from 15.5 ± 0.53% to 13.7 ± 0.55% (FAC) and from 16.7 ± 0.97% to 12.7 ± 1.0% (PA), respectively, p < 0.05). Recombinant TNF-T with PA and FAC has protected the B-cell component of the immune system from this negative immunosuppressive effect. CD20 level in group A after the treatment PA + TNF-T was 15.0 ± 1.0%, after FAC + TNF-T was 15.4 ± 1.4% which were different significantly from those in group B (p < 0.05).

Conclusions: The proposed method of the local application of recombinant hybrid protein of TNF-T has a mainly immunostimulant effect on B-cell component of the immune system.